The aim of the Cancer-ID program is to develop novel technology for monitoring Cancer therapy through revealing the extracellular vesicle IDentity (Cancer-ID). Novel technology platforms will be developed and validated for detection and detailed molecular characterization of cancer-associated EV. Isolation of EV from body fluids and staining protocols will be optimized, thereby enabling the optical, mechanical, biochemical characterization of EV, or sorted subpopulations thereof. This will enable the development of both macro and micro-fluidic devices to enumerate EVs, establish the cellular origin of single EV, and extract relevant information. These platforms will enable personalized medicine by efficiently monitoring disease development and therapeutic effectiveness, which will improve health care efficacy and reduce costs, thus ultimately improving the quality of life of patients.